Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Opus Genetics, Inc.

Market Cap 329M 284M 262M 245M 459M 31.26B 466M 3.09B 1.2B 15.21B 1.23B 1.21B 52.68B P/E Ratio 2026 *
-3.76x
P/E Ratio 2027 * -5.44x
Enterprise Value 329M 284M 262M 245M 459M 31.26B 466M 3.09B 1.2B 15.21B 1.23B 1.21B 52.68B EV / Sales 2026 *
21.6x
EV / Sales 2027 * 21.4x
Free-Float
88.78%
Yield 2026 *
-
Yield 2027 * -
1 day+3.32%
1 week+0.25%
Current month-7.34%
1 month-22.01%
3 months-16.53%
6 months+71.19%
Current year+101.00%
1 week 3.83
Extreme 3.83
4.24
1 month 3.83
Extreme 3.83
5.15
Current year 1.88
Extreme 1.88
5.81
1 year 0.9
Extreme 0.9011
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
7
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 2023-10-31
Director of Finance/CFO 51 2025-09-01
President 60 2024-10-21
Director TitleAgeSince
Director/Board Member 77 2020-10-31
Chairman 56 2019-11-30
Director/Board Member 59 2020-10-31
Date Insider Type Main position Quantity % Market Cap.
05-17
The Foundation Fighting Blindness, Inc.
SellCompany -1,700,000 2.0886%
04-22Sell

Chief Financial Officer

7,842 0.0110%
04-22Sell

Chief Technology Officer

7,542 0.0106%
Change 5-day change 1-year change 3-year change Capi.($)
+3.32%+0.25%+307.42%+5.48% 318M
-2.41%+0.14%+39.53%+154.43% 1,035B
+1.07%+3.48%+53.75%+50.64% 574B
+1.32%+0.22%+18.35%+65.35% 397B
+0.77%0.00%+19.99%+16.80% 324B
-1.42%-1.44%+45.50%+8.37% 298B
-0.85%-2.86%+22.05%+13.80% 281B
+0.44%+3.48%+24.48%+34.39% 278B
+1.66%+1.20%-44.67%-47.49% 193B
+0.32%+1.61%+19.48%+63.42% 191B
Average +0.08%-0.71%+50.59%+36.52% 357.22B
Weighted average by Cap. -0.82%+1.00%+30.04%+66.96%

Financials

2026 *2027 *
Net sales 15.21M 13.14M 12.11M 11.33M 21.24M 1.45B 21.56M 143M 55.73M 704M 57.08M 55.87M 2.44B 15.39M 13.29M 12.25M 11.46M 21.48M 1.46B 21.81M 145M 56.37M 712M 57.74M 56.51M 2.46B
Net income -94.99M -82.04M -75.6M -70.77M -133M -9.03B -135M -893M -348M -4.39B -357M -349M -15.22B -67.85M -58.6M -54M -50.55M -94.73M -6.45B -96.2M -638M -249M -3.14B -255M -249M -10.87B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
26-06-12 4.040 $ +3.32% 689,872
26-06-11 3.910 $ +0.51% 553,681
26-06-10 3.890 $ -4.66% 819,056
26-06-09 4.080 $ +1.24% 803,671
26-06-08 4.030 $ 0.00% 536,218
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
4.040USD
Average target price
10.47USD
Spread / Average Target
+159.17%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!